Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions

Anna Vildhede, Maria Karlsgren, Elin K. Svedberg, Jacek R. Wisniewski, Yurong Lai, Agneta Norén, and Per Artursson

Department of Pharmacy, Uppsala University, Sweden (A.V, M.K, E.K.S, P.A); Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP) - a node of the Chemical Biology Consortium Sweden (M.K, P.A); Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried D 82152, Germany (J.R.W); Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut 06340, USA (Y.L); and Department of Surgery, Uppsala University, 751 85 Uppsala, Sweden (A.N)

Primary laboratory of origin: Department of Pharmacy, Uppsala University, Sweden
DPBS Dulbecco’s phosphate buffered saline
HBSS Hank’s balanced salt solution
IC\textsubscript{50} half-maximal inhibitory concentration
KHB Krebs-Henseleit bicarbonate
K\textsubscript{m} Michaelis-Menten constant
MTA maximal transport activity
NTCP sodium taurocholate co-transporting polypeptide
OATP organic anion transporting polypeptide
ORF open reading frame
SLC solute carrier
UPLC-MS/MS ultra-high performance liquid chromatography tandem mass spectrometry
V\textsubscript{max} maximal uptake rate
Abstract

Differences in the expression and function of the organic anion transporting polypeptide (OATP) transporters contribute to inter-individual variability in atorvastatin clearance.

However, the importance of the bile acid transporter NTCP (SLC10A1) in atorvastatin uptake clearance (CL_{upt}) is not yet clarified. To elucidate this issue, we investigated the relative contribution of NTCP, OATP1B1, OATP1B3, and OATP2B1 to atorvastatin CL_{upt} in twelve human liver samples. The impact of inhibition on atorvastatin CL_{upt} was also studied, using inhibitors of different isoform specificities. Expression levels of the four transport proteins were quantified by LC-MS/MS. These data, together with atorvastatin in vitro kinetics, were used to predict the maximal transport activity (MTA) and inter-individual differences in CL_{upt} of each transporter in vivo. Subsequently, hepatic uptake impairment upon co-administration of five clinically interacting drugs was predicted using in vitro inhibitory potencies. NTCP and OATP protein expression varied 3.7- to 32-fold among the twelve sample donors. The rank order in expression was OATP1B1 > OATP1B3 ≈ NTCP ≈ OATP2B1. NTCP was found to be of minor importance in atorvastatin disposition. Instead, OATP1B1 and OATP1B3 were confirmed as the major atorvastatin uptake transporters. The average contribution to atorvastatin uptake was OATP1B1 > OATP1B3 >> OATP2B1 > NTCP, although this rank order varied between individuals. The inter-individual differences in transporter expression and CL_{upt} resulted in marked differences in drug-drug interactions due to isoform-specific inhibition. We conclude that this variation should be considered in in vitro to in vivo extrapolations.
Introduction

Transporter-mediated hepatic uptake of atorvastatin is the rate-determining step in the elimination of the drug in vitro (Watanabe et al., 2010) and in vivo (Maeda et al., 2011). At least four members of the SLC superfamily transport atorvastatin in various in vitro systems. These are the three organic anion transporting polypeptide transporters, OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1) (Choi et al., 2011; Karlgren et al., 2012b; Konig, 2011), and the sodium taurocholate co-transporting polypeptide (NTCP, SLC10A1) (Choi et al., 2011). All four proteins are expressed in the basolateral membrane of human hepatocytes, where they mediate uptake of substrates into the hepatocytes from the blood (Cui et al., 2003; Keitel et al., 2005).

The importance of OATP1B1 in the hepatic uptake has been emphasized, since OATP1B1 genetic variants with reduced function and OATP inhibition have been associated with greater systemic exposure of atorvastatin in clinical studies (Lau et al., 2007; Pasanen et al., 2007). However, in a recent study, NTCP was shown to contribute significantly to the hepatic uptake of three different statins (pitavastatin, fluvastatin, and rosuvastatin) with 24-45 % of overall active uptake (Bi et al., 2013). These results indicate that NTCP may play a more important role in statin uptake than previously assumed. The importance of NTCP in atorvastatin uptake has not yet been clarified and needs to be addressed.

In the present study, we investigated the contribution of NTCP to hepatic atorvastatin uptake using a protein expression based prediction model (Karlgren et al., 2012b) and in vitro hepatocyte experiments. We combined in vitro uptake kinetics with protein quantification to assess the contribution of each transporter to atorvastatin uptake clearance (CLupt) in livers from twelve individuals with varying expression of the four uptake transporters. We also investigated the influence of inter-individual transporter expression and isoform-specific inhibition on atorvastatin clearance at clinically relevant concentrations.
Materials and Methods

Compounds

Atorvastatin was kindly provided by AstraZeneca (Mölndal, Sweden). Atazanavir was acquired from Toronto Research Chemicals Inc. (Toronto, ON, Canada). Cyclosporine, gemfibrozil and rifampicin were purchased from Sigma-Aldrich (St. Louis, MO, USA), and lopinavir from Abbott Laboratories (Chicago, IL, USA). All other chemicals were of analytical grade and purchased from commercial sources.

Cloning and establishment of stable NTCP-HEK293 cells

Total human liver RNA was obtained from Clontech (Mountain View, CA, USA). cDNA was generated by reverse transcription using the SuperScript III first-strand synthesis supermix (Invitrogen, Carlsbad, CA, USA). A NTCP-pcDNA5/FRT vector was constructed in two steps. First, the NTCP open reading frame (ORF) was amplified from the human liver cDNA using Platinum Pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA) and the gene-specific primer pair 5'-CTAGAAGCTTATGGAGGCCCACAACGCGTC-3'/5'-CTAGGGTACCCTGGTCTGCAAGGGGAGCTAGTC-3'. Restriction sites introduced by the primers are underlined. The PCR product was cloned into the HindIII/KpnI site of the vector p3xFLAG-CMV14 (Sigma-Aldrich, St. Louis, MO, USA). The inserted NTCP ORF was verified by DNA sequencing analysis and found to be identical to the NCBI SLC10A1 reference sequence (NM_003049).

Next, the NTCP-p3xFLAG-CMV14 was used as template in a second amplification step with Platinum Pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA) and the primer pair 5'-CTAGAAGCTTATGGAGGCCCACAACGCGTC-3'/5'-CTAGGGTACCCTCGGCTGTAAGGGGAGCGCATG-3'. HindIII and XhoI restriction sites introduced by the primers are underlined. The PRC product, consisting of the NTCP ORF with a FLAG-tag, was cloned into the HindIII/XhoI site of the expression vector.
pcDNA5/FRT (Invitrogen, Carlsbad, CA, USA). The inserted sequence was verified by DNA sequencing analysis. Human embryonic kidney (HEK) Flp-In-293 cells (Invitrogen, Carlsbad, CA, USA) were transfected with the constructed NTCP-pcDNA5/FRT expression vector and further selected using hygromycin B (Invitrogen, Carlsbad, CA, USA) as previously described (Karlgren et al., 2012a).

**Cell cultivation**

Mock-transfected HEK Flp-In-293 cells and cells stably expressing NTCP or either of the three OATP transporters (established and characterized by (Karlgren et al., 2012a; Karlgren et al., 2012b)) were cultivated as described elsewhere (Karlgren et al., 2012a). Passages between 10 and 30 were used throughout the study.

**Transport experiments in HEK293 cells**

Two days before transport experiments, OATP2B1-expressing cells were seeded in 96-well CellBind plates (Corning, Amsterdam, Netherlands) at a density of 100,000 cells per well. Cells expressing NTCP, OATP1B1, or OATP1B3 were seeded in 24-well plates at a density of 600,000 cells per well two (OATP1B1, NTCP) or three days (OATP1B3) before the experiments. For all cultures in 96- or 24-well plates, Flp-In medium without phenol red and hygromycin B was used. Cell density was optimized by a computer assisted experimental design (MODDE 7.0, Umetrics, Umeå, Sweden) (Karlgren et al., 2012a).

The following experimental procedure was used in both the kinetic and inhibition experiments. At start of the experiment, cells were washed twice with pre-warmed Hank’s balanced salt solution (HBSS), pH 7.4, followed by incubation with pre-warmed substrate or substrate/inhibitor solutions for 2 min at 37 °C. The incubation was terminated by adding ice-cold Dulbecco’s phosphate buffered saline (DPBS), followed by two-three washes with ice-cold DPBS. The cells were dried and the intracellular drug accumulation was quantified by ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
All transport experiments in HEK293 cells were run in duplicate (24-well format) or triplicate (96-well format) on at least two independent separate occasions.

**Kinetic characterization of NTCP- and OATP-mediated atorvastatin uptake**

The uptake of atorvastatin in HEK293 cells stably expressing NTCP was linear up to 6 min in the concentration range of 0.1-800 µM (data not shown). To assess the kinetics of the NTCP-mediated uptake of atorvastatin, we incubated NTCP-HEK293 cells for 2 min with increasing concentration of atorvastatin (0.1-500 µM). Initial uptake rate was plotted against substrate concentration. The resulting uptake curve was fitted to the Michaelis-Menten equation with the addition of a non-saturable passive diffusion rate component (Equation 1) using GraphPad Prism v.5.04 (GraphPad Software, La Jolla, CA, USA).

\[
V = \frac{V_{\text{max}} \times [S]}{K_m + [S]} + P_{\text{diff}} \times [S] \quad \text{Eq. 1}
\]

where \(V\) is the uptake rate, \(V_{\text{max}}\) is the maximal uptake rate (at saturating substrate concentration), \([S]\) is the substrate concentration, \(K_m\) is the substrate concentration at which the uptake rate is half of \(V_{\text{max}}\) and \(P_{\text{diff}}\) is the passive diffusion.

The Michaelis Menten kinetics of OATP1B1-, OATP1B3-, and OATP2B1-mediated uptake of atorvastatin have been previously determined (Karlgren et al., 2012a; Karlgren et al., 2012b). \(K_m\) and \(V_{\text{max}}\) data were used from these studies.

**Concentration-dependent inhibition of NTCP- and OATP-mediated atorvastatin uptake**

The half-maximal inhibitory concentrations, IC\(_{50}\)-values, of atazanavir, cyclosporine, gemfibrozil, lopinavir, and rifampicin for NTCP-, OATP1B1-, OATP1B3-, and OATP2B1-mediated atorvastatin uptake were determined \textit{in vitro} using stably transfected HEK293 cells overexpressing each of the transporters. The inhibitors were selected to cover three well-known clinically interacting drugs causing \textit{in vivo} atorvastatin AUC changes to varying extent.
(cyclosporine, gemfibrozil, and rifampicin). In addition, two drugs (atazanavir and lopinavir) that interact clinically with other statins were included.

Substrate concentration was set to 1 µM and uptake was measured at seven to twelve inhibitor concentrations: 0.01-40 µM (atazanavir), 0.01-25 µM (cyclosporine), 0.01-1000 µM (gemfibrozil), 0.01-10 µM (lopinavir), and 0.01-630 µM (rifampicin). Cells incubated with 1 µM atorvastatin were used as a reference in the calculations of the remaining active uptake in the presence of the compound of interest. In all experiments, uptake in mock-transfected cells was subtracted from the total uptake to correct for the passive permeability. The resulting inhibition data were fitted to Equation 2 using GraphPad Prism v.5.04 (GraphPad Software, La Jolla, CA, USA) to estimate an IC₅₀-value.

\[
\text{Substrate uptake (% of control)} = \frac{100}{1 + 10^{(\log[I] - \log(IC₅₀) \times \text{Hill slope})}} \tag{Eq. 2}
\]

where \([I]\) is the inhibitor concentration and the Hill slope describes the steepness of the curve. The equation is equal to the four-parameter equation when the top plateau of the curve is constrained to 100 % and the bottom plateau is fixed to 0 % in the data fitting.

As previously defined, a compound was considered to be a specific inhibitor of a transporter if the IC₅₀-value was at least 10-fold lower than the IC₅₀-values of the other three transporters (Karlgren et al., 2012b). On the basis of the IC₅₀-values, corresponding inhibition constants, \(K_i\), were calculated assuming competitive inhibition (Equation 3).

\[
K_i = \frac{IC₅₀}{\left(\frac{[S]}{K_m} + 1\right)} \tag{Eq. 3}
\]

**UPLC-MS/MS analysis**

Intracellular atorvastatin was extracted with 200 µl acetonitrile/water (60/40) spiked with 50 nM warfarin as internal standard, followed by centrifugation at 2465 x g at 4 °C for 20 min. Atorvastatin concentration in the supernatant was determined using UPLC-MS/MS.
with the following analytical system: Acquity UPLC with a reversed phase BEH C18 column (2.1 x 50 mm, particle size 1.7 µm) (Waters, Milford, MA, USA) and a mobile gradient consisting of acetonitrile, formic acid and water, coupled to a Waters Xevo triple quadrupole with electrospray ionization interface.

Protein concentration

In all uptake kinetic or inhibition experiments, total protein content was measured in representative wells using the BCA Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, USA).

Human liver tissue

Normal excess human liver tissue was obtained from liver resections carried out at the Department of Surgery, Uppsala University Hospital (Uppsala, Sweden), as approved by Uppsala Regional Ethical Review Board (ethical approval no. 2009/028). All donors gave their informed consent. Twelve snap-frozen liver biopsy samples were used for analysis of hepatic protein expression. Another five human liver tissue specimens were used for hepatocyte isolation and subsequent uptake experiments. A summary of donor characteristics can be found in Supplemental Table 1. All donors were of Caucasian origin. The donors had no history of HIV or hepatitis.

Transport experiments in human hepatocytes

Primary hepatocytes were isolated using a two-step collagenase perfusion technique described elsewhere (Lecluyse et al., 2010). The cells were suspended in DMEM supplemented with 5 % FBS, penicillin-streptomycin (PEST, 100 U ml⁻¹ and 100 µg ml⁻¹, respectively), 4 µg ml⁻¹ insulin and 1 µM dexamethasone, and plated on collagen I-coated 24-well plates (BD Biosciences, Franklin Lakes, NJ, USA) at a density of 375,000 cells per well. The cells were allowed to attach for 3 h at 37 °C and 5 % CO₂ atmosphere. After attachment, the medium was replaced with Hepatocyte Maintenance Medium (Lonza, Basel, Switzerland)
supplemented with PEST, insulin-transferrin-selenium (10 µg ml⁻¹, 5.5 µg ml⁻¹, and 5 ng ml⁻¹, respectively) and 0.1 µM dexamethasone.

**NTCP-mediated uptake of atorvastatin**

Twenty-four hours post-seeding, the cells were washed twice with either pre-warmed modified Krebs-Henseleit bicarbonate (KHB) buffer (1.2 mM MgSO₄, 0.96 mM KH₂PO₄, 4.83 mM KCl, 118 mM NaCl, 1.53 mM CaCl₂, 23.8 mM NaHCO₃, 12.5 mM HEPES, 5 mM glucose, pH 7.4) or sodium-free KHB (NaCl and NaCHO₃ replaced with choline chloride and KHCO₃ respectively, pH 7.4). This was followed by a pre-incubation with the sodium-containing/sodium-free KHB for 10 min at 37 °C. Pre-incubation medium was removed and drug transport was initiated by adding either atorvastatin (1 µM) or taurocholate (1 µM) in KHB or sodium-free KHB. Substrate concentration was selected to be in the vicinity of transporter Km (linear range) without violating the limit of detection in the mass spectrometric analysis. Uptake was terminated after 2 min by adding ice-cold DPBS. Cells were washed three times with DPBS and then dried. Intracellular accumulation of atorvastatin and taurocholate was determined with UPLC-MS/MS as described above. The experiment was run in quadruplicate on two separate occasions using hepatocytes isolated from two different donors.

**Inhibition of atorvastatin uptake**

At start of the experiment, cells were washed twice with pre-warmed HBSS, pH 7.4, followed by incubation with pre-warmed substrate or substrate/inhibitor solutions for 0.5, 1, 1.5 or 2 min at 37 °C. Atorvastatin concentration was set to 1 µM for reasons explained above. Since the hepatocyte experiments required a higher substrate concentration than that reached *in vivo* (due to sensitivity limitations in the mass spectrometric analysis), inhibitor concentration was scaled up to three times the predicted unbound inlet concentration to the liver in order to give a similar extent of uptake inhibition as in our *in vivo* predictions. Uptake...
was terminated at designated time points by adding ice-cold DPBS, followed by three washes. Acetonitrile was added to stop atorvastatin metabolism and was then let to evaporate. Intracellular drug accumulation was quantified by UPLC-MS/MS as described above. Atorvastatin uptake was plotted against incubation time and initial uptake rate in absence and presence of inhibitor was determined from the slope of the curves. The experiment was run in triplicate on three separate occasions using hepatocytes isolated from two different donors and one in-house batch of cryopreserved hepatocytes from a third donor.

**Quantitative protein expression analysis**

*Targeted protein quantification of NTCP in human liver and in NTCP-HEK293 cells*

HEK293 cells stably transfected with NTCP were harvested and frozen down as previously described for HEK-OATP cells (Karlgren *et al.*, 2012b). Membrane fractions from the pellet of HEK293 cells were extracted and digested with trypsin using the protocol by Qui and colleagues (Qiu *et al.*, 2013). The plasma membrane constituted approximately 10% of the crude membrane fraction analyzed. The abundance of NTCP in HEK293 cells stably expressing the transporter relative to that in a representative human liver sample (previously prepared and analyzed for OATP1B1, OATP1B3 and OATP2B1 protein expression (Karlgren *et al.*, 2012b)) was determined by peptide-based LC-MS/MS measurements. An isotope-labeled peptide, unique for NTCP, was used as an internal standard to quantify the corresponding surrogate peptide of NTCP protein in both the cell line and human liver sample. Each sample was analyzed in duplicate (technical repeats).

*Quantitative proteomic analysis of inter-individual differences in protein expression in the human liver samples*

The protein expression levels of NTCP, OATP1B1, OATP1B3, and OATP2B1 in twelve human liver samples was determined from previously obtained in-depth label-free mass
s spectrometry data (Karlgren et al., 2012b) using the total protein approach (TPA) as described by (Wisniewski et al., 2012).

**In vitro to in vivo extrapolations**

**Prediction of hepatic intrinsic uptake clearance from protein expression levels**

Hepatic intrinsic uptake clearance (CL\textsubscript{int, uptake}) of atorvastatin was predicted from the maximal transport activity (MTA), calculated according to Equation 4 (Karlgren et al., 2012b). Briefly, the ratio of the protein expression in a representative human liver sample to that in the overexpressing cell line (obtained using targeted peptide-based protein quantification) was used as a scaling factor to convert the maximal transport rate observed \textit{in vitro} to a theoretical maximal transport activity \textit{in vivo} (see Equation 5).

\[
\text{CL}_{\text{int, uptake}} = \sum_{\text{transporters}} \frac{\text{MTA}}{K_m + [S]} \times \text{HomPPGL}
\]

\textit{Eq. 4}

where [S] is the maximal unbound plasma concentration of atorvastatin and HomPPGL is milligrams of homogenate protein per gram of liver tissue.

\[
\text{MTA} = \frac{\text{Protein expression}_{\text{in vivo}}}{\text{Protein expression}_{\text{in vitro}}} \times V_{\text{max (in vitro)}}
\]

\textit{Eq. 5}

Using previously determined MTA values for atorvastatin transport by OATP1B1, OATP1B3, and OATP2B1 (Karlgren et al., 2012b), and the MTA value obtained herein for NTCP, we predicted the intrinsic uptake clearance in the reference liver tissue sample. Uptake clearance for each of the twelve individuals was then predicted from the relative protein expression between different individuals, using the representative liver sample as reference.

**Prediction of drug-drug interactions**

\textit{In vitro} inhibition data (K\textsubscript{i}), were used to predict the impact of inhibition on atorvastatin intrinsic uptake clearance according to Equation 6 (Karlgren et al., 2012b).
\[
\text{CL}_{\text{int, inhibitor}} = \sum_{\text{transporters}} \frac{\text{CL}_{\text{int, uptake}}}{[I] + K_i} \quad \text{Eq. 6}
\]

The inhibitor concentration \([I]\) in the predictions was the estimated maximal unbound concentration of the inhibitor at the inlet to the liver \((I_{u, \text{max}, \text{in}})\), as reported by (Yoshida et al., 2012).

**Data presentation and statistical analysis**

Data are expressed as means ± standard deviations, unless otherwise stated. Differences in hepatic uptake in the presence and absence of sodium were assessed using Student’s t-test. Results were deemed significant at \(P < 0.05\).
Results

Atorvastatin uptake in NTCP- and OATP-HEK293 cells

Atorvastatin uptake was 8-fold higher in cells expressing NTCP compared to mock-transfected cells (Figure 1A). The uptake followed Michaelis-Menten kinetics (Figure 1B). The $K_m$ was determined to $185 \pm 108 \mu M$ and $V_{max}$ to $2260 \pm 1184 \text{ pmol min}^{-1} \text{ mg protein}^{-1}$, respectively (Table 1). OATP1B1-, OATP1B3-, and OATP2B1-mediated atorvastatin uptake kinetics have been determined previously (Karlgren et al., 2012b) and are given in Table 1.

Inter-individual variability in protein expression of OATP1B1, OATP1B3, OATP2B1, and NTCP in human liver samples

Twelve human liver tissue samples were analyzed for expression of NTCP, OATP1B1, OATP1B3, and OATP2B1 using label-free mass spectrometry. The four transport proteins were detected in all twelve samples. The rank order in expression was OATP1B1 > OATP1B3 $\approx$ NTCP $\approx$ OATP2B1 (Figure 2A-D and Table 2). All of the uptake transporters displayed considerable variability in protein expression between the twelve individuals, ranging from 3.7-fold (OATP1B1) to 32-fold (OATP1B3), Table 2. However, the summed expression of the four transporters in the twelve livers only varied 2.3-fold.

Predictions of the intrinsic uptake clearance and contribution of NTCP, OATP1B1, OATP1B3, and OATP2B1 to atorvastatin uptake in vivo

The contribution of NTCP, OATP1B1, OATP1B3, and OATP2B1 to atorvastatin uptake in vivo (Figure 3) was predicted from atorvastatin uptake kinetics (Table 3) by correcting for the difference in membrane protein expression between the cell lines and the human liver samples. NTCP was predicted to play a minor role in the uptake with 1.5 to 10 % of total transporter-mediated uptake. Instead, OATP1B1 and OATP1B3 were confirmed to be the major uptake transporters with relative contributions of 26 to 89 and 1.8 to 60 % to the total
active uptake, respectively. In three of the twelve individuals (subject 5, 6 and 9), OATP1B3 was the primary transporter responsible for atorvastatin uptake into the liver. In contrast, the third hepatic OATP transporter, OATP2B1, generally played a less important role in the uptake with 3.2-30 % of total active uptake, (Figure 3). The rank order in average contribution was OATP1B1 > OATP1B3 >> OATP2B1 > NTCP.

For the twelve livers studied, a mean atorvastatin intrinsic uptake clearance of 2030 mL min^{-1} was predicted (95 % CI 1440-2620 mL min^{-1}). Assuming the same passive diffusion of atorvastatin across the cell membrane of hepatocytes and HEK293 cells, transporter-mediated active uptake was predicted to dominate with 90 ± 2 % (85-93 %) of overall atorvastatin uptake.

**NTCP-mediated uptake of atorvastatin in human hepatocytes**

NTCP has been shown to play a more significant role in the uptake of pitavastatin, fluvastatin, and rosuvastatin than what we predicted for atorvastatin. We therefore further investigated the validity of our predictions by studies in human hepatocytes. In this model, the sodium independent OATP transporters are active in parallel with the sodium-dependent NTCP. Hence, removal of sodium ions would incapacitate the NTCP transporter, but not the OATP transporters.

No significant difference in atorvastatin uptake in sodium-containing as compared to sodium-free buffer was observed, while the uptake of the prototypical NTCP substrate taurocholate was reduced by more than 50 % after removal of sodium, Figure 4 (P < 0.001). This result is consistent with our predictions of a low contribution of NTCP to hepatic atorvastatin accumulation.

**Inhibition of NTCP- and OATP-mediated atorvastatin uptake in vitro**

The dose-dependent inhibition of NTCP-, OATP1B1-, OATP1B3-, and OATP2B1-mediated atorvastatin uptake in HEK293 cells with atazanavir, cyclosporine, gemfibrozil,
lopinavir, and rifampicin is presented in Figure 5A-E. These drugs inhibit plasma clearance of atorvastatin or other statins in clinical DDI studies. The corresponding IC$_{50}$-values are summarized in Table 3. We defined an inhibitor as selective if the IC$_{50}$-value was at least 10 times lower than those of the other three transporters. On the basis of this definition, atazanavir, lopinavir and rifampicin were defined as selective OATP1B1 inhibitors for atorvastatin uptake (Figure 5A, D, and E). On the other hand, OATP2B1- and NTCP-mediated atorvastatin uptake was stimulated by rifampicin in a dose-dependent manner (Figure 5E). All of the uptake transporters, except for OATP2B1, were strongly inhibited by cyclosporine (Figure 5B). In contrast, gemfibrozil only interacted weakly with OATP1B1-, OATP2B1-, and NTCP-mediated transport of atorvastatin (IC$_{50}$ > 50 µM), Figure 5C.

**Predictions of the influence of DDIs on atorvastatin uptake clearance**

The influence of co-administration of atazanavir, cyclosporine, gemfibrozil, lopinavir, or rifampicin on hepatic atorvastatin uptake clearance at clinically relevant concentrations was predicted for each human liver sample (Figure 6). In these predictions, the maximal unbound inlet concentration to the liver was used as inhibitor concentration, while maximal unbound plasma concentration was used for atorvastatin. Due to the variability in protein expression and isoform-specific inhibition (see above), marked differences in inhibition patterns were observed. For instance, co-administration of cyclosporine (an inhibitor of NTCP, OATP1B1, and OATP1B3) resulted in a low variability in inter-individual inhibition (40-57 % remaining active uptake clearance). In contrast, the OATP1B1 specific inhibitors atazanavir, lopinavir, and rifampicin showed greater variability between individuals with 20-57, 33-76, and 36-81 % remaining active uptake CL, respectively.

This can be explained by the isoform specificity of these compounds. While cyclosporine inhibits both OATP1B1 and OATP1B3 with similar potency, atazanavir, lopinavir, and rifampicin inhibit OATP1B1 with much higher potencies than OATP1B3. The summed
contribution of OATP1B1 and OATP1B3 to atorvastatin uptake CL showed lower inter-individual variability than the OATP1B1 contribution alone for these twelve livers. Hence, as illustrated here by atazanavir, lopinavir, and rifampicin, large differences in isoform-specific inhibitor potencies translate to high inter-individual variability in the inhibition of the hepatic atorvastatin uptake (Figure 6).

Overall, co-administration with atazanavir, an inhibitor with a relatively high estimated concentration at the inlet to the liver, was predicted to give the largest effect on atorvastatin uptake. Gemfibrozil, on the other hand, was predicted to have a minimal effect on atorvastatin uptake clearance due to its weak or non-existing inhibition of OATP1B1, OATP1B3, OATP2B1, and NTCP.

**Inhibition of atorvastatin uptake in human hepatocytes**

To verify our DDI predictions, we investigated the inhibition of the initial atorvastatin uptake in human hepatocytes from three donors (Figure 7). Two of the hepatocyte batches were used directly after isolation and one was a cryopreserved plateable batch from our collection of human hepatocytes. The uptake of atorvastatin was linear up to 2 min. The measured atorvastatin uptake clearance without inhibition was 5-12 µl min⁻¹ mg protein⁻¹, which is similar to that measured independently in sandwich-cultured hepatocytes (unpublished data kindly provided by Dr. El-Kattan, Pfizer). In line with our predictions, cyclosporine was found to inhibit the uptake of atorvastatin by 44-74 % while gemfibrozil did not inhibit the uptake at all. Atazanavir inhibited the uptake by 26-45 %, i.e. in the lower range of our predictions. The other two inhibitors showed less inhibition than predicted from the liver tissue samples (lopinavir 0-30 %, and rifampicin 0-21 %).
Discussion

In a previous study, we introduced an expression based model to assess the contribution of each OATP to atorvastatin uptake clearance in vivo (Karlgren et al., 2012b). Herein, we applied this model to study inter-individual differences in atorvastatin uptake clearance using liver tissue samples from twelve individuals. We also determined the contribution of NTCP to hepatic atorvastatin uptake for the first time.

NTCP and OATP protein levels were determined by label-free mass spectrometry. Our measured transporter abundances were comparable to previously reported hepatic expression data, albeit we find higher levels of OATP1B1 (Bi et al., 2013; Kimoto et al., 2012; Ohtsuki et al., 2012; Prasad et al., 2013). We speculate that this could be a result of the sample preparation used here (Wisniewski et al., 2009), including the membrane fractionation, solubilization and tryptic digestion. The higher expression of OATP1B1 relative to NTCP, OATP1B3, and OATP2B1 confirms its importance in hepatic drug disposition.

Consistent with other reports (Nies et al., 2013), we noted considerable inter-individual variability in transporter expression. The observed variability can be a result of e.g. differences in gene regulation, polymorphisms and/or epigenetic profiles (Ivanov et al., 2012; Nies et al., 2013) but it was outside the scope of this study to investigate this further.

Transporter abundances were used to determine the contribution of each transporter to atorvastatin uptake. Our method of predicting transporter contribution to uptake clearance builds on the assumptions that all protein quantified in the isolated membrane fraction is available to transport (Karlgren et al., 2012b). Intracellular pools or post-translationally inactivated protein is not accounted for. Hence, the term maximal transport activity (MTA), which represents an upper limit in transport capacity. Although OATP transporters are reported not to be stored in intracellular vesicular compartments, NTCP has been shown to be subject to recycling from endosomal compartments (Roma et al., 2008). It can thus not be
excluded that the abundance of NTCP in the cell membrane was overestimated. Nevertheless, this does not influence the interpretation of the results, since the contribution of NTCP to atorvastatin uptake was minor.

Interestingly, the contribution of NTCP to atorvastatin uptake was much lower than previously reported for pitavastatin, fluvastatin and rosuvastatin (Bi et al., 2013). Instead, we confirmed that OATP1B1 and OATP1B3 were the primary transporters involved in atorvastatin uptake in vivo. The importance of OATP1B1 in hepatic atorvastatin uptake has been emphasized in other studies (Amundsen et al., 2010; Pasanen et al., 2007), but our data suggest that OATP1B3 is almost as important. The relatively high contribution of OATP1B3 to the uptake of atorvastatin differs from other statins, such as simvastatin acid and pitavastatin (Elsby et al., 2012; Hirano et al., 2004). This observation is supported by a study on clinical pharmacokinetics of atorvastatin, in which OATP1B1 was predicted to account for 47% of the total atorvastatin hepatic uptake (Shitara et al., 2013). We attribute the remainder of the active uptake mainly to OATP1B3.

In contrast to OATP1B1 and OATP1B3, the third OATP transporter, OATP2B1, did not contribute substantially to hepatic uptake of atorvastatin. Instead, OATP2B1 may be important in the uptake of statins into skeletal muscle cells. OATP2B1 expression has been localized to the sarcolemmal membrane of human skeletal muscle fibers, suggesting that this protein has a key role in statin-related adverse effects in this tissue (Knauer et al., 2010). OATP2B1 is also expressed in the human intestine and has been found to alter the AUC of drugs such as fexofenadine (Imanaga et al., 2011). It may thus have an important role in intestinal absorption of statins.

Transporter-mediated drug-drug interactions were predicted for a set of clinical inhibitors with different isoform specificity using in vitro inhibitory data. Since OATP inhibition is substrate-dependent (e.g. (Noe et al., 2007; Soars et al., 2012)), the in vitro inhibitory
capacity was determined with atorvastatin as the victim drug. There were clear differences in OATP inhibition pattern when using atorvastatin as substrate instead of prototypical model substrates (Table 4). For instance, atazanavir, cyclosporine, and rifampicin showed a strong-to-moderate inhibition of OATP2B1-mediated uptake of estrone-3-sulphate, but no inhibition of atorvastatin transport. The substrate-dependent inhibition observed here and by others could be a result of multiple binding sites/domains on the OATP transporters (Miyagawa et al., 2009; Noe et al., 2007). We therefore recommend using substrates of concern, rather than model substrates, in in vitro studies aiming to predict in vivo interactions.

Atorvastatin uptake increased in the presence of rifampicin in a concentration-dependent manner in OATP2B1- and NTCP-expressing HEK293 cells. Since the contribution of these transporters to overall atorvastatin uptake was limited, this stimulation was not accounted for in our DDI predictions. Stimulation of OATP uptake has been reported previously in in vitro studies (Grube et al., 2006). To our knowledge, though, it has never been observed in vivo. There is evidence of in vivo stimulation of efflux transport by the multidrug resistance associated protein 2 (MRP2) in rats (Heredi-Szabo et al., 2009), but the degree of potentiation is much less than that observed in vitro in the same study.

Marked differences in the predicted extent of drug-drug interactions were observed between the individuals as a result of the variability in transporter contribution to atorvastatin uptake (Figure 6). This illustrates the importance of investigating the relative contribution of all transporters involved in the uptake of drug substrates in order to correctly assess the impact of drug-drug interactions of various isoform-specific inhibitors. Our MTA-based approach can easily be applied for this purpose and gives accurate predictions of transporter contribution without the need of either in vivo studies of reduced function genetic variants or human hepatocyte experiments with transporter-specific substrates (relative activity factor (RAF)) (Hirano et al., 2004). It should be noted that the expression-based scaling factor is in
*vitro* system-specific and thus needs to be determined for each cell line used. Once it has been established though, it can be applied to any substrate.

*In vitro* experiments in human hepatocytes confirmed our DDI predictions. Although the hepatocytes were isolated from different tissue samples than those used for our predictions, the results were in good agreement. Lopinavir and rifampicin, though, gave less inhibition than predicted and the inhibition by atazanavir was in the lower range of our predictions. This could indicate that the hepatic OATP1B1 expression/availability was lower in these hepatocyte batches than in the human liver tissue samples (Kimoto *et al.*, 2012; Lundquist *et al.*, 2014).

The DDI predictions were included to illustrate the possible consequence of large inter-individual variability in transporter expression on the extent of impaired hepatic uptake, potentially translating to variability in systemic exposure. Our predictions agreed qualitatively with clinical observations. Gemfibrozil was predicted to have a low impact on atorvastatin uptake CL *in vivo*. The reported AUC changes upon concomitant administration of this drug with atorvastatin are also relatively small (1.2- to 1.4-fold) (Backman *et al.*, 2005; Whitfield *et al.*, 2011)). In contrast, cyclosporine and rifampicin were predicted to reduce the hepatic uptake by approximately 50 % and these compounds increase atorvastatin AUC to a large extent *in vivo* (>7-fold AUC change, (Asberg *et al.*, 2001; He *et al.*, 2009; Hermann *et al.*, 2004; Lau *et al.*, 2007; Lemahieu *et al.*, 2005)). Although hepatic uptake plays a major role in clinically observed drug-drug interactions with atorvastatin as the victim drug, inhibition of CYP3A4-mediated metabolism and efflux in both the intestine and liver is likely to contribute to the AUC changes seen *in vivo*. Gemfibrozil and rifampicin are CYP3A4 non-inhibitors (Maeda *et al.*, 2011; Wen *et al.*, 2001), but cyclosporine is a potent inhibitor of CYP3A4 and its pronounced effect on atorvastatin AUC may reflect this complexity.
In conclusion, the present study showed that quantification of drug transport protein expression can advance our understanding of inter-individual differences in hepatic uptake and drug-drug interactions. We found substantial differences in the expression of NTCP, OATP1B1, OATP1B3, and OATP2B1 in twelve human liver samples. As a consequence, the contribution of these transporters to hepatic uptake influenced the potential for DDI with co-administered drugs at the individual level. We confirm a dominating role of OATP1B1 and OATP1B3 in the uptake clearance of atorvastatin, while NTCP and OATP2B1 play minor roles. Our study provides proof-of-concept that differences in transporter expression must be taken into account in predictions of variability in drug clearance and clinical drug-drug interactions for drugs that are substrates of several transporters.
Acknowledgements

The authors gratefully acknowledge Drs. Ulf Haglund, Frans Duraj and Jozef Urdzik at Uppsala University Hospital for their skillful contribution in clinical sampling. We are indebted to Drs. Xi Qiu and Emi Kimoto at Pfizer for their contribution to the protein quantification. Dr. Ewa Ellis at Karolinska Institutet is acknowledged for kindly providing one of the hepatocyte batches used in the DDI experiments. The authors also thank Cherendeep Dhanda for her valuable contribution in transport experiments.
**Authorship Contributions**

Participated in research design: Vildhede, Karlgren, Artursson

Conducted experiments: Vildhede, Karlgren, Svedberg, Wisniewski, Lai, Norén

Contributed new reagents or analytical tools: Wisniewski, Lai

Performed data analysis: Vildhede

Wrote or contributed to the writing of the manuscript: Vildhede, Karlgren, Svedberg, Wisniewski, Lai, Norén, Artursson
References


Footnotes

This work was supported by the Swedish Research Council [grant approval no. 2822]; the Swedish Fund for Research without Animal Experiments; the Lars Hierta Memorial Foundation; and O.E. and Edla Johansson’s Scientific Foundation.

Part of this work was presented at the joint 19th MDO and 12th European ISSX Meeting 2012.

Person to receive reprint requests:

Per Artursson, PhD, Professor in Dosage Form Design
Department of Pharmacy, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden
Email: per.artursson@farmaci.uu.se

Present address of Y.L: Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey, USA.
Legends for Figures

Figure 1. Atorvastatin uptake in NTCP-HEK293 cells. (A) Uptake of atorvastatin in cells expressing NTCP compared to passive uptake in mock-transfected cells. Data represent the mean and standard deviation of 12 independent experiments, each run in triplicate. (B) Kinetic profile of NTCP-mediated uptake of atorvastatin and passive diffusion in mock-transfected cells. Atorvastatin uptake in HEK293 cells either stably transfected with NTCP or mock-transfected was measured over a range of ten concentrations between 0.1 and 800 µM. Data represent the uptake rate measured in duplicate in one representative experiment.

Figure 2. Label-free protein quantification of uptake transporters in human liver tissue.
Protein expression levels of OATP1B1 (A), OATP1B3 (B), OATP2B1 (C), and NTCP (D) in crude membrane fractions from twelve human livers. Protein abundance were calculated from the ratio of the summed signal intensities of the peptides identifying each protein to the signal intensities of all peptides identified for the human liver proteome (> 4000 proteins). The last bar represents the arithmetic mean expression for the twelve samples with standard deviation.

Figure 3. Atorvastatin hepatic uptake. Prediction of in vivo intrinsic hepatic uptake clearance (CL int,uptake) of atorvastatin based on protein expression data in human liver and in vitro cell models. The dotted line represents the mean intrinsic uptake CL for the twelve livers. The hepatic clearance via passive diffusion (CLpassive) was predicted to be the same as that observed in HEK293 cells (120 µL min⁻¹ g liver⁻¹). OATP1B1 and OATP1B3 were predicted to contribute to the majority of the hepatic atorvastatin uptake.

Figure 4. Atorvastatin and taurocholate uptake in human hepatocytes in sodium-containing (control) and sodium-free buffer after 2 min incubation with a concentration of 1 µM. Data
shown as mean ± S.D (n=4) from a representative experiment. *** P<0.001 compared with control.

Figure 5. Inhibition of OATP1B1-, OATP1B3-, OATP2B1- and NTCP-mediated uptake of atorvastatin by atazanavir (A), cyclosporine (B), gemfibrozil (C), lopinavir (D), and rifampicin (E) in stably transfected HEK293 cells. The cells were incubated with 1 µM atorvastatin and increasing concentrations of the potential inhibitors for 2 min at 37 °C. Data represent mean ± S.E.M.

Figure 6. Impact of drug-drug interactions on predicted atorvastatin uptake clearance.

Remaining intrinsic uptake clearance upon co-administration of five different inhibitors is shown for the twelve livers. Co-administration of gemfibrozil was predicted to have a minor impact on atorvastatin uptake CL, while co-administration of atazanavir, cyclosporine, lopinavir, and rifampicin was predicted to give a more pronounced reduction in atorvastatin uptake.

Figure 7. Inhibition of atorvastatin uptake by atazanavir, cyclosporine, gemfibrozil, lopinavir and rifampicin in human hepatocytes. Atorvastatin (1 µM) was incubated in the presence and absence of the potential inhibitors. Uptake clearance was determined from the slope of the curves. Data shown as mean ± S.D (n=3) from a representative experiment.
### Tables

Table 1. Kinetic parameters of NTCP-, OATP1B1-, OATP1B3-, and OATP2B1-mediated atorvastatin uptake in stably transfected HEK293 cells.

<table>
<thead>
<tr>
<th>Transporter</th>
<th>K_m (µM)</th>
<th>V_max (pmol min^{-1} mg protein^{-1})</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTCP</td>
<td>185 ± 108</td>
<td>2260 ± 1184</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>0.77 ± 0.24(^a)</td>
<td>6.61 ± 1.24(^a)</td>
</tr>
<tr>
<td>OATP1B3</td>
<td>0.73 ± 1.45(^a)</td>
<td>10.12 ± 1.78(^a)</td>
</tr>
<tr>
<td>OATP2B1</td>
<td>2.84 ± 1.63(^a)</td>
<td>455.2 ± 55.36(^a)</td>
</tr>
</tbody>
</table>

\(^a\) K_m and V_max values reprinted with permission from (Karlgren et al., 2012b). Copyright (2012) American Chemical Society.
Table 2. Protein expression levels of uptake transporters in human liver membrane fractions.

<table>
<thead>
<tr>
<th>Transporter</th>
<th>n</th>
<th>Protein expression level (fmol µg membrane protein(^{-1}))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean ± S.D  Median  Min  Max  Max/Min</td>
</tr>
<tr>
<td>NTCP</td>
<td>12</td>
<td>1.8 ± 0.5   1.2   0.5   3.9   7.5</td>
</tr>
<tr>
<td>OATP1B1</td>
<td>12</td>
<td>23.2 ± 9.4  19.6  12.1  44.4  3.7</td>
</tr>
<tr>
<td>OATP1B3</td>
<td>12</td>
<td>3.2 ± 0.2   3.8   0.2   6.0   32.0</td>
</tr>
<tr>
<td>OATP2B1</td>
<td>12</td>
<td>1.6 ± 0.6   1.5   0.6   4.3   7.5</td>
</tr>
</tbody>
</table>

Max, maximum; Min, minimum; Max/Min, fold range in expression
Table 3. Half-maximal inhibitory concentrations, IC$_{50}$, and corresponding inhibition constants, K$_i$, calculated assuming competitive inhibition.

<table>
<thead>
<tr>
<th></th>
<th>OATP1B1</th>
<th>OATP1B3</th>
<th>OATP2B1</th>
<th>NTCP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IC$_{50}$ (µM)</td>
<td>K$_i$ (µM)</td>
<td>IC$_{50}$ (µM)</td>
<td>K$_i$ (µM)</td>
</tr>
<tr>
<td>Atazanavir</td>
<td>0.96</td>
<td>0.42</td>
<td>17</td>
<td>7.3</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>1.5</td>
<td>0.66</td>
<td>3.1</td>
<td>1.3</td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>130</td>
<td>58</td>
<td>&gt;1000</td>
<td>&gt;420</td>
</tr>
<tr>
<td>Lopinavir</td>
<td>0.77</td>
<td>0.34</td>
<td>&gt;10</td>
<td>&gt;4.2</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>5.0</td>
<td>2.2</td>
<td>190</td>
<td>82</td>
</tr>
</tbody>
</table>
Table 4. Comparison of half-maximal inhibitory concentrations, IC$_{50}$, determined *in vitro* using either atorvastatin or an endogenous substrate.

<table>
<thead>
<tr>
<th></th>
<th>OATP1B1</th>
<th>OATP1B3</th>
<th>OATP2B1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IC$_{50}$ (µM)</td>
<td>IC$_{50}$ (µM)</td>
<td>IC$_{50}$ (µM)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>0.96 ± 1.2</td>
<td>1.4 ± 1.0</td>
<td>17 ± 1.3</td>
</tr>
<tr>
<td>E17βG$^a$</td>
<td>1.4 ± 1.2</td>
<td>3.1 ± 1.4</td>
<td>1.3 ± 1.0</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>1.5 ± 1.2</td>
<td>1.4 ± 1.2</td>
<td>190 ± 1.7</td>
</tr>
<tr>
<td>E17βG$^a$</td>
<td>1.2 ± 1.2</td>
<td>1.2 ± 1.2</td>
<td>3.1 ± 1.4</td>
</tr>
</tbody>
</table>

E17βG, estradiol-17β-glucuronide; E3S, estrone-3-sulphate

$^a$ IC$_{50}$-values reprinted with permission from (Karlgren *et al.*, 2012b). Copyright (2012) American Chemical Society.
Figure 1

A

Atorvastatin uptake (relative units)

B

Uptake rate (pmol/min/mg protein)

Atorvastatin concentration (μM)
Figure 2

A. OATP1B1

B. OATP1B3

C. OATP2B1

D. NTCP

[Bar charts showing protein expression levels for each liver sample and average for each transporter.]
Figure 4

![Uptake (% of control)]

- **Atorvastatin**
  - + Na⁺
  - - Na⁺

- **Taurocholate**
  - + Na⁺
  - - Na⁺

*Significance levels: ***p < 0.001*
Figure 5

A. Atazanavir
B. Cyclosporine
C. Gemfibrozil
D. Lopinavir
E. Rifampicin

Substrate uptake (% of control) vs. Concentration (μM)

Legend:
- □ NTCP
- OATP1B1
- OATP1B3
- OATP2B1
Figure 7

[Graph showing the effects of various inhibitors on atorvastatin uptake over time (0.5 to 2.0 min). Different markers represent different inhibitors: No inhibitor, Atazanavir, Cyclosporine, Gemfibrozil, Lopinavir, Rifampicin.]